论文部分内容阅读
目的:观察古方青娥丸对绝经后骨质疏松症患者的临床疗效及骨转换标志物、骨桥蛋白的影响,探讨青娥丸改善绝经后骨质疏松症的作用机制。方法:选择绝经后骨质疏松症患者64例,随机分为青娥丸治疗组(治疗组)及模拟剂治疗组(对照组)治疗6个月。分别在治疗前后检测患者骨密度、骨转换标志物(PINP,S-CTX)、雌激素以及骨桥蛋白的浓度。结果:治疗组在治疗前后骨密度及骨形成标志物PINP、雌激素未见明显变化,骨吸收标志物S-CTX水平显著降低(P<0.05),骨桥蛋白水平亦显著降低(P<0.05);对照组骨密度持续下降,骨转化标志物及骨桥蛋白、雌激素水平无显著性差异。结论:古方青娥丸能够维持绝经后骨质疏松症患者的骨密度、抑制骨吸收,可能与抑制骨桥蛋白的表达有关。
Objective: To observe the effect of Gufang Qing’e pill on postmenopausal osteoporosis in patients with clinical efficacy and bone turnover markers, osteopontin, to explore the Qingmo pills to improve the mechanism of postmenopausal osteoporosis. Methods: Sixty-four patients with postmenopausal osteoporosis were selected and randomly divided into two groups: treatment group (treatment group) and treatment group (control group) for 6 months. The bone mineral density, bone turnover markers (PINP, S-CTX), estrogen and osteopontin concentrations were measured before and after treatment. Results: There was no significant change in bone mineral density and bone morphogenetic protein PINP and estrogen in the treatment group before and after treatment. The levels of bone resorption markers S-CTX were significantly decreased (P <0.05) and osteopontin level was significantly decreased (P <0.05 ). The BMD of the control group continued to decrease, and there was no significant difference between the bone turnover markers and osteopontin and estrogen levels. Conclusion: Gufang Qing’ewan can maintain the bone mineral density and inhibit bone resorption in postmenopausal osteoporosis patients, which may be related to the inhibition of osteopontin expression.